Last 12 months
Inside the activity.
0 purchase rows · 75 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 8 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 7 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2021 Filed Jul 27, 2021 20:49 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 3,425 | $69.02 | $236,393.50 |
DisclosureSEC source: 0001127602-21-022506 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,148 Read SEC document |
| July 24, 2021 Filed Jul 27, 2021 20:49 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 7,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-022506 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 01:22 UTC |
Lofton Kevin EDirector
|
GrantPhantom Stock · Derivative | 30.1326 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021092 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,913.0962 Underlying: Common Stock · 30.1326 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 18:33 UTC |
Rodriguez JavierDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-020005 · form4.xml · derivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,223 Underlying: Common Stock · 1,838 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on June 15, 2021. F2 · derivative.expiration_date: 100% of the restricted stock units vested on June 15, 2021. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 18:33 UTC |
Rodriguez JavierDirector
|
Exercise / conversionCommon Stock | 1,838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-020005 · form4.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:52 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-019794 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,290 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:52 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 1,605 | $69.29 | $111,210.45 |
DisclosureSEC source: 0001127602-21-019794 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,971 Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:52 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-019794 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 12, 2021 Filed May 14, 2021 19:56 UTC |
WELTERS ANTHONYDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016781 · form4.xml · derivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 19:56 UTC |
WELTERS ANTHONYDirector
|
GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016781 · form4.xml · derivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,591 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 19:58 UTC |
Rodriguez JavierDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016783 · form4.xml · derivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 19:58 UTC |
Rodriguez JavierDirector
|
GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016783 · form4.xml · derivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:01 UTC |
MANWANI HARISHDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016788 · form4.xml · derivative · entry 2 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:01 UTC |
MANWANI HARISHDirector
|
GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016788 · form4.xml · derivative · entry 1 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,223 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:04 UTC |
Lofton Kevin EDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016797 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:04 UTC |
Lofton Kevin EDirector
|
GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016797 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,053 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:22 UTC |
Bluestone JeffreyDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016844 · form4.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:22 UTC |
Bluestone JeffreyDirector
|
GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016844 · form4.xml · derivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,264 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:11 UTC |
Kramer Kelly A.Director
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016816 · form4.xml · derivative · entry 2 Kramer Kelly A. · CIK 0001629885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:11 UTC |
Kramer Kelly A.Director
|
GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016816 · form4.xml · derivative · entry 1 Kramer Kelly A. · CIK 0001629885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,953 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:15 UTC |
Horning SandraDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016827 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:15 UTC |
Horning SandraDirector
|
GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016827 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,159 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:27 UTC |
BARTON JACQUELINE KDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016858 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:27 UTC |
BARTON JACQUELINE KDirector
|
GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016858 · form4.xml · derivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,776 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:50 UTC |
MANWANI HARISHDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-015950 · form4.xml · derivative · entry 2 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,936 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vested on May 6, 2021. F2 · derivative.expiration_date: 100% of the restricted stock units will vested on May 6, 2021. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:50 UTC |
MANWANI HARISHDirector
|
Exercise / conversionCommon Stock | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-015950 · form4.xml · nonDerivative · entry 1 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:53 UTC |
Whitley Richard JamesDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-015952 · form4.xml · derivative · entry 2 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,028 Underlying: Common Stock · 1,936 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 6, 2021. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 6, 2021. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:53 UTC |
Whitley Richard JamesDirector
|
Exercise / conversionCommon Stock | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-015952 · form4.xml · nonDerivative · entry 1 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:59 UTC |
BARTON JACQUELINE KDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-015954 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,553 Underlying: Common Stock · 1,936 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 6, 2021. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 6, 2021. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:59 UTC |
BARTON JACQUELINE KDirector
|
Exercise / conversionCommon Stock | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-015954 · form4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 06, 2021 Filed May 7, 2021 23:02 UTC |
WOLD OLSEN PERDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-015956 · form4.xml · derivative · entry 2 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,936 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 6, 2021. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 6, 2021. Read SEC document |
| May 06, 2021 Filed May 7, 2021 23:02 UTC |
WOLD OLSEN PERDirector
|
Exercise / conversionCommon Stock | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-015956 · form4.xml · nonDerivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:02 UTC |
Mercier JohannaChief Commercial Officer
|
SaleCommon Stock | 19,496 | $66.09 | $1,288,547.18 |
DisclosureSEC source: 0001127602-21-015567 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,068 F1 · price: Sale prices reported for the transactions reported here range from $66.08 to $66.115. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 03, 2021 Filed May 4, 2021 22:37 UTC |
Whitley Richard JamesDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 20,282 | $0.00 Strike: $20.65 | $0.00 |
DisclosureSEC source: 0001127602-21-015340 · form4.xml · derivative · entry 3 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,282 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 12, 2012. Read SEC document |
| May 03, 2021 Filed May 4, 2021 22:37 UTC |
Whitley Richard JamesDirector
|
SaleCommon Stock | 20,282 | $64.57 | $1,309,655.39 |
DisclosureSEC source: 0001127602-21-015340 · form4.xml · nonDerivative · entry 2 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,122 F1 · price: Sale prices reported for the transactions reported here range from $64.56 to $64.64. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 03, 2021 Filed May 4, 2021 22:37 UTC |
Whitley Richard JamesDirector
|
Exercise / conversionCommon Stock | 20,282 | $20.65 | $418,721.89 |
DisclosureSEC source: 0001127602-21-015340 · form4.xml · nonDerivative · entry 1 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 23:47 UTC |
Whitley Richard JamesDirector
|
GrantPhantom Stock · Derivative | 62.9649 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012440 · form4.xml · derivative · entry 1 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,871.6977 Underlying: Common Stock · 62.9649 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 23:50 UTC |
Lofton Kevin EDirector
|
GrantPhantom Stock · Derivative | 30.9153 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012442 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,882.9636 Underlying: Common Stock · 30.9153 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:39 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
SaleCommon Stock | 1,486 | $63.36 | $94,152.96 |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · nonDerivative · entry 4 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,166 F4 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:39 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 72,855 | $0.00 Strike: $63.91 | $0.00 |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · derivative · entry 7 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,855 Underlying: Common Stock · 72,855 shares Expires 2031-03-10 F7 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:39 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
GrantRestricted Stock Unit · Derivative | 12,520 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · derivative · entry 6 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,751 Underlying: Common Stock · 12,520 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F6 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F6 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:39 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · derivative · entry 5 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,231 Underlying: Common Stock · 2,593 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F5 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F5 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:39 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Tax withholdingCommon Stock | 1,107 | $63.91 | $70,748.37 |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,652 Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:39 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionCommon Stock | 2,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:42 UTC |
Parsey MerdadChief Medical Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 96,760 | $0.00 Strike: $63.91 | $0.00 |
DisclosureSEC source: 0001127602-21-010476 · form4.xml · derivative · entry 6 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,760 Underlying: Common Stock · 96,760 shares Expires 2031-03-10 F6 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:42 UTC |
Parsey MerdadChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 16,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010476 · form4.xml · derivative · entry 5 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,189 Underlying: Common Stock · 16,625 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F5 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% will vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F5 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% will vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:42 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010476 · form4.xml · derivative · entry 4 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,564 Underlying: Common Stock · 3,455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four- year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four- year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:42 UTC |
Parsey MerdadChief Medical Officer
|
Tax withholdingCommon Stock | 1,639 | $63.91 | $104,748.49 |
DisclosureSEC source: 0001127602-21-010476 · form4.xml · nonDerivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,079 Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:42 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionCommon Stock | 3,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010476 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
GrantRestricted Stock Unit · Derivative | 5,085 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010481 · form4.xml · derivative · entry 5 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,387 Underlying: Common Stock · 5,085 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.